Predictors of lower exercise capacity in patients with cancer.

Humans Exercise Tolerance Hand Strength Troponin T Neoplasms Body Mass Index

Journal

Scientific reports
ISSN: 2045-2322
Titre abrégé: Sci Rep
Pays: England
ID NLM: 101563288

Informations de publication

Date de publication:
08 09 2023
Historique:
received: 23 02 2023
accepted: 25 08 2023
medline: 11 9 2023
pubmed: 9 9 2023
entrez: 8 9 2023
Statut: epublish

Résumé

Maintaining cancer patients' exercise capacity and therefore patients' ability to live a self-determined life is of huge importance, but little is known about major determinants. We sought to identify determinants of exercise capacity in patients with a broad spectrum of cancer types, who were already receiving cancer treatment or about to commence such therapy. Exercise capacity was assessed in 253 consecutive patients mostly suffering from advanced cancer using the 6-min walk test (6-MWT). All patients underwent echocardiography, physical examination, resting electrocardiogram, hand grip strength (HGS) measurement, and laboratory assessments. Patients were divided into two groups according to the median distance in the 6-MWT (459 m). Patients with lower exercise capacity were older, had significantly lower HGS and haemoglobin and higher values of high sensitive (hs) Troponin T and NT-proBNP (all p < 0.05). Whilst the co-morbidity burden was significantly higher in this group, no differences were detected for sex, body mass index, tumor type, or cachexia (all p > 0.2). Using multivariable logistic regression, we found that the presence of anaemia (odds ratio (OR) 6.172, 95% confidence interval (CI) 1.401-27.201, p = 0.016) as well as an increase in hs Troponin T (OR 3.077, 95% CI 1.202-5.301, p = 0.019) remained independent predictors of impaired exercise capacity. Increasing HGS was associated with a reduced risk of a lower exercise capacity (OR 0.896, 95% CI 0.813-0.987, p = 0.026). Screening patients for elevated hs troponin levels as well as reduced HGS may help to identify patients at risk of lower exercise capacity during cancer treatment.

Identifiants

DOI: 10.1038/s41598-023-41390-0 PMID: 37684302 PMC: PMC10491652
pubmed: 37684302
doi: 10.1038/s41598-023-41390-0
pii: 10.1038/s41598-023-41390-0
pmc: PMC10491652
doi:

Substances chimiques

Troponin T 0

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

14861

Informations de copyright

© 2023. Springer Nature Limited.

Références

Mattiuzzi, C. & Lippi, G. Current cancer epidemiology. J. Epidemiol. Glob. Health 9, 217–222. https://doi.org/10.2991/jegh.k.191008.001 (2019).
doi: 10.2991/jegh.k.191008.001 pubmed: 31854162 pmcid: 7310786
Ewer, M. S. & Ewer, S. M. Cardiotoxicity of anticancer treatments: What the cardiologist needs to know. Nat. Rev. Cardiol. 7, 564–575. https://doi.org/10.1038/nrcardio.2010.121 (2010).
doi: 10.1038/nrcardio.2010.121 pubmed: 20842180
Anker, M. S., von Haehling, S., Landmesser, U., Coats, A. J. S. & Anker, S. D. Cancer and heart failure-more than meets the eye: Common risk factors and co-morbidities. Eur. J. Heart Fail. 20, 1382–1384. https://doi.org/10.1002/ejhf.1252 (2018).
doi: 10.1002/ejhf.1252 pubmed: 29943887
Ameri, P. et al. Cancer diagnosis in patients with heart failure: Epidemiology, clinical implications and gaps in knowledge. Eur. J. Heart Fail. 20, 879–887. https://doi.org/10.1002/ejhf.1165 (2018).
doi: 10.1002/ejhf.1165 pubmed: 29464808
Sung, H. et al. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J. Clin. 71, 209–249. https://doi.org/10.3322/caac.21660 (2021).
doi: 10.3322/caac.21660 pubmed: 33538338
Anker, M. S., Hulsmann, M. & Cleland, J. G. What do patients with heart failure die from? A single assassin or a conspiracy?. Eur. J. Heart Fail. 22, 26–28. https://doi.org/10.1002/ejhf.1689 (2020).
doi: 10.1002/ejhf.1689 pubmed: 31863684
Evertz, R. et al. Cardiovascular and metabolic determinants of quality of life in patients with cancer. ESC Heart Fail. https://doi.org/10.1002/ehf2.14175 (2022).
doi: 10.1002/ehf2.14175 pubmed: 36178215 pmcid: 9871717
Buffart, L. M. et al. Effects and moderators of exercise on quality of life and physical function in patients with cancer: An individual patient data meta-analysis of 34 RCTs. Cancer Treat. Rev. 52, 91–104. https://doi.org/10.1016/j.ctrv.2016.11.010 (2017).
doi: 10.1016/j.ctrv.2016.11.010 pubmed: 28006694
Cramer, L. et al. Cardiovascular function and predictors of exercise capacity in patients with colorectal cancer. J. Am. Coll. Cardiol. 64, 1310–1319. https://doi.org/10.1016/j.jacc.2014.07.948 (2014).
doi: 10.1016/j.jacc.2014.07.948 pubmed: 25257631
von Haehling, S. et al. Improving exercise capacity and quality of life using non-invasive heart failure treatments: Evidence from clinical trials. Eur. J. Heart Fail. 23, 92–113. https://doi.org/10.1002/ejhf.1838 (2021).
doi: 10.1002/ejhf.1838
Marcoa, R. et al. Classification of chronic obstructive pulmonary disease (COPD) according to the new global initiative for chronic obstructive lung disease (GOLD) 2017: Comparison with GOLD 2011. COPD 15, 21–26. https://doi.org/10.1080/15412555.2017.1394285 (2018).
doi: 10.1080/15412555.2017.1394285 pubmed: 29161163
Williams, B. et al. 2018 ESC/ESH Guidelines for the management of arterial hypertension. The Task Force for the management of arterial hypertension of the European Society of Cardiology (ESC) and the European Society of Hypertension (ESH). Ital. Cardiol. (Rome) 19, 3S-73S. https://doi.org/10.1714/3026.30245 (2018).
doi: 10.1714/3026.30245
ATS Committee on Proficiency Standards for Clinical Pulmonary Function Laboratories. ATS statement: Guidelines for the six-minute walk test. Am. J. Respir. Crit. Care Med. 166, 111–117. https://doi.org/10.1164/ajrccm.166.1.at1102 (2002).
doi: 10.1164/ajrccm.166.1.at1102
Ness, K. K. et al. Exercise intolerance, mortality, and organ system impairment in adult survivors of childhood cancer. J. Clin. Oncol. 38, 29–42. https://doi.org/10.1200/JCO.19.01661 (2020).
doi: 10.1200/JCO.19.01661 pubmed: 31622133
Cormie, P., Zopf, E. M., Zhang, X. & Schmitz, K. H. The impact of exercise on cancer mortality, recurrence, and treatment-related adverse effects. Epidemiol. Rev. 39, 71–92. https://doi.org/10.1093/epirev/mxx007 (2017).
doi: 10.1093/epirev/mxx007 pubmed: 28453622
Banzer, W. et al. Changes in exercise capacity, quality of life and fatigue in cancer patients during an intervention. Eur. J. Cancer Care (Engl.) 23, 624–629. https://doi.org/10.1111/ecc.12201 (2014).
doi: 10.1111/ecc.12201 pubmed: 24724813
Miller, A. M. et al. Exercise capacity in long-term survivors of pediatric cancer: An analysis from the Cardiac Risk Factors in Childhood Cancer Survivors Study. Pediatr. Blood Cancer 60, 663–668. https://doi.org/10.1002/pbc.24410 (2013).
doi: 10.1002/pbc.24410 pubmed: 23255294
deFilippi, C. R. et al. Physical activity, change in biomarkers of myocardial stress and injury, and subsequent heart failure risk in older adults. J. Am. Coll. Cardiol. 60, 2539–2547. https://doi.org/10.1016/j.jacc.2012.08.1006 (2012).
doi: 10.1016/j.jacc.2012.08.1006 pubmed: 23158528 pmcid: 3591516
Eggers, K. M., Venge, P., Lindahl, B. & Lind, L. Cardiac troponin I levels measured with a high-sensitive assay increase over time and are strong predictors of mortality in an elderly population. J. Am. Coll. Cardiol. 61, 1906–1913. https://doi.org/10.1016/j.jacc.2012.12.048 (2013).
doi: 10.1016/j.jacc.2012.12.048 pubmed: 23500239
Waschki, B. et al. High-sensitivity troponin I and all-cause mortality in patients with stable COPD: An analysis of the COSYCONET study. Eur. Respir. J. https://doi.org/10.1183/13993003.01314-2019 (2020).
doi: 10.1183/13993003.01314-2019 pubmed: 31831579
Lorente-Ros, A. et al. Myocardial injury determination improves risk stratification and predicts mortality in COVID-19 patients. Cardiol. J. 27, 489–496. https://doi.org/10.5603/CJ.a2020.0089 (2020).
doi: 10.5603/CJ.a2020.0089 pubmed: 32589258 pmcid: 8078990
Dierkes, J. et al. Cardiac troponin T predicts mortality in patients with end-stage renal disease. Circulation 102, 1964–1969. https://doi.org/10.1161/01.cir.102.16.1964 (2000).
doi: 10.1161/01.cir.102.16.1964 pubmed: 11034946
Hudson, M. P. et al. Implications of elevated cardiac troponin T in ambulatory patients with heart failure: A prospective analysis. Am. Heart J. 147, 546–552. https://doi.org/10.1016/j.ahj.2003.10.014 (2004).
doi: 10.1016/j.ahj.2003.10.014 pubmed: 14999208
Lippi, G., Cervellin, G. & Sanchis-Gomar, F. Predicting mortality with cardiac troponins: Recent insights from meta-analyses. Diagnosis (Berl) 8, 37–49. https://doi.org/10.1515/dx-2019-0061 (2021).
doi: 10.1515/dx-2019-0061 pubmed: 31622246
Lyon, A. R. et al. ESC guidelines on cardio-oncology developed in collaboration with the European Hematology Association (EHA), the European Society for Therapeutic Radiology and Oncology (ESTRO) and the International Cardio-Oncology Society (IC-OS). Eur. Heart J. https://doi.org/10.1093/eurheartj/ehac244 (2022).
doi: 10.1093/eurheartj/ehac244 pubmed: 36017568
Cardinale, D. et al. Prognostic value of troponin I in cardiac risk stratification of cancer patients undergoing high-dose chemotherapy. Circulation 109, 2749–2754. https://doi.org/10.1161/01.CIR.0000130926.51766.CC (2004).
doi: 10.1161/01.CIR.0000130926.51766.CC pubmed: 15148277
Lyon, A. R. et al. Baseline cardiovascular risk assessment in cancer patients scheduled to receive cardiotoxic cancer therapies: A position statement and new risk assessment tools from the Cardio-Oncology Study Group of the Heart Failure Association of the European Society of Cardiology in collaboration with the International Cardio-Oncology Society. Eur. J. Heart Fail. 22, 1945–1960. https://doi.org/10.1002/ejhf.1920 (2020).
doi: 10.1002/ejhf.1920 pubmed: 32463967
Ludwig, H. et al. The European Cancer Anaemia Survey (ECAS): A large, multinational, prospective survey defining the prevalence, incidence, and treatment of anaemia in cancer patients. Eur. J. Cancer 40, 2293–2306. https://doi.org/10.1016/j.ejca.2004.06.019 (2004).
doi: 10.1016/j.ejca.2004.06.019 pubmed: 15454256
Ament, W. & Verkerke, G. J. Exercise and fatigue. Sports Med. 39, 389–422. https://doi.org/10.2165/00007256-200939050-00005 (2009).
doi: 10.2165/00007256-200939050-00005 pubmed: 19402743
Mayer, G., Thum, J. & Graf, H. Anaemia and reduced exercise capacity in patients on chronic haemodialysis. Clin. Sci. (Lond.) 76, 265–268. https://doi.org/10.1042/cs0760265 (1989).
doi: 10.1042/cs0760265 pubmed: 2924518
Ebner, N. et al. The impact of iron deficiency and anaemia on exercise capacity and outcomes in patients with chronic heart failure. Results from the studies investigating co-morbidities aggravating heart failure. Int. J. Cardiol. 205, 6–12. https://doi.org/10.1016/j.ijcard.2015.11.178 (2016).
doi: 10.1016/j.ijcard.2015.11.178 pubmed: 26705670
Piepoli, M. F., Corra, U. & Agostoni, P. Cardiopulmonary exercise testing in patients with heart failure with specific comorbidities. Ann. Am. Thorac. Soc. 14, S110–S115. https://doi.org/10.1513/AnnalsATS.201610-803FR (2017).
doi: 10.1513/AnnalsATS.201610-803FR pubmed: 28380304
Kalra, P. R. et al. Effect of anemia on exercise tolerance in chronic heart failure in men. Am. J. Cardiol. 91, 888–891. https://doi.org/10.1016/s0002-9149(03)00030-4 (2003).
doi: 10.1016/s0002-9149(03)00030-4 pubmed: 12667582
Drouin, J. S. et al. Random control clinical trial on the effects of aerobic exercise training on erythrocyte levels during radiation treatment for breast cancer. Cancer 107, 2490–2495. https://doi.org/10.1002/cncr.22267 (2006).
doi: 10.1002/cncr.22267 pubmed: 17031805
Hu, M. & Lin, W. Effects of exercise training on red blood cell production: Implications for anemia. Acta Haematol. 127, 156–164. https://doi.org/10.1159/000335620 (2012).
doi: 10.1159/000335620 pubmed: 22301865
Szachniewicz, J. et al. Anaemia is an independent predictor of poor outcome in patients with chronic heart failure. Int. J. Cardiol. 90, 303–308. https://doi.org/10.1016/s0167-5273(02)00574-0 (2003).
doi: 10.1016/s0167-5273(02)00574-0 pubmed: 12957766
Anker, S. D. et al. Ferric carboxymaltose in patients with heart failure and iron deficiency. N. Engl. J. Med. 361, 2436–2448. https://doi.org/10.1056/NEJMoa0908355 (2009).
doi: 10.1056/NEJMoa0908355 pubmed: 19920054
Ponikowski, P. et al. Beneficial effects of long-term intravenous iron therapy with ferric carboxymaltose in patients with symptomatic heart failure and iron deficiencydagger. Eur. Heart J. 36, 657–668. https://doi.org/10.1093/eurheartj/ehu385 (2015).
doi: 10.1093/eurheartj/ehu385 pubmed: 25176939
Kyomoto, Y. et al. Handgrip strength measurement in patients with chronic obstructive pulmonary disease: Possible predictor of exercise capacity. Respir. Investig. 57, 499–505. https://doi.org/10.1016/j.resinv.2019.03.014 (2019).
doi: 10.1016/j.resinv.2019.03.014 pubmed: 31085119
Kim, W. et al. Handgrip strength as a predictor of exercise capacity in coronary heart disease. J. Cardiopulm Rehabil. Prev. 40, E10–E13. https://doi.org/10.1097/HCR.0000000000000458 (2020).
doi: 10.1097/HCR.0000000000000458 pubmed: 32118655
Jakobsen, L. H., Rask, I. K. & Kondrup, J. Validation of handgrip strength and endurance as a measure of physical function and quality of life in healthy subjects and patients. Nutrition 26, 542–550. https://doi.org/10.1016/j.nut.2009.06.015 (2010).
doi: 10.1016/j.nut.2009.06.015 pubmed: 19804953
Kim, H., Yoo, S., Kim, H., Park, S. G. & Son, M. Cancer survivors with low hand grip strength have decreased quality of life compared with healthy controls: The Korea National Health and Nutrition Examination Survey 2014–2017. Korean J. Fam. Med. 42, 204–211. https://doi.org/10.4082/kjfm.20.0060 (2021).
doi: 10.4082/kjfm.20.0060 pubmed: 34038988 pmcid: 8164921
Paek, J. & Choi, Y. J. Association between hand grip strength and impaired health-related quality of life in Korean cancer survivors: A cross-sectional study. BMJ Open 9, e030938. https://doi.org/10.1136/bmjopen-2019-030938 (2019).
doi: 10.1136/bmjopen-2019-030938 pubmed: 31501128 pmcid: 6738715
Zhuang, C. L. et al. Associations of low handgrip strength with cancer mortality: A multicentre observational study. J. Cachexia Sarcopenia Muscle 11, 1476–1486. https://doi.org/10.1002/jcsm.12614 (2020).
doi: 10.1002/jcsm.12614 pubmed: 32910535 pmcid: 7749566
Kilgour, R. D. et al. Handgrip strength predicts survival and is associated with markers of clinical and functional outcomes in advanced cancer patients. Support Care Cancer 21, 3261–3270. https://doi.org/10.1007/s00520-013-1894-4 (2013).
doi: 10.1007/s00520-013-1894-4 pubmed: 23872952
Hadzibegovic, S. et al. Hand grip strength in patients with advanced cancer: A prospective study. J. Cachexia Sarcopenia Muscle https://doi.org/10.1002/jcsm.13248 (2023).
doi: 10.1002/jcsm.13248 pubmed: 37318103 pmcid: 10401539

Auteurs

Ruben Evertz (R)

Department of Cardiology and Pneumology, University of Göttingen Medical Center (UMG), Georg-August-University Göttingen, Robert-Koch-Str. 40, 37075, Göttingen, Germany.
German Center for Cardiovascular Research (DZHK), Partner Site Göttingen, Göttingen, Germany.
ORCID: 0000-0002-5904-4652

Christine Diehl (C)

Department of Cardiology and Pneumology, University of Göttingen Medical Center (UMG), Georg-August-University Göttingen, Robert-Koch-Str. 40, 37075, Göttingen, Germany.
Department of Paediatrics, University of Göttingen Medical Center (UMG), 37075, Göttingen, Germany.

Katharina Gödde (K)

Department of Cardiology and Pneumology, University of Göttingen Medical Center (UMG), Georg-August-University Göttingen, Robert-Koch-Str. 40, 37075, Göttingen, Germany.

Miroslava Valentova (M)

Department of Cardiology and Pneumology, University of Göttingen Medical Center (UMG), Georg-August-University Göttingen, Robert-Koch-Str. 40, 37075, Göttingen, Germany.
German Center for Cardiovascular Research (DZHK), Partner Site Göttingen, Göttingen, Germany.

Tania Garfias-Veitl (T)

Department of Cardiology and Pneumology, University of Göttingen Medical Center (UMG), Georg-August-University Göttingen, Robert-Koch-Str. 40, 37075, Göttingen, Germany.
German Center for Cardiovascular Research (DZHK), Partner Site Göttingen, Göttingen, Germany.

Tobias R Overbeck (TR)

Department of Haematology and Medical Oncology, University of Göttingen Medical Center (UMG), 37075, Göttingen, Germany.
Comprehensive Cancer Center G-CCC, Medical Center (UMG), University of Göttingen, 37075, Göttingen, Germany.

Friederike Braulke (F)

Comprehensive Cancer Center G-CCC, Medical Center (UMG), University of Göttingen, 37075, Göttingen, Germany.

Alessia Lena (A)

Charité - Universitätsmedizin Berlin, Corporate Member of Freie Universität Berlin and Humboldt-Universität zu Berlin, Charitéplatz 1, 10117, Berlin, Germany.
Deutsches Herzzentrum der Charité, Klinik für Kardiologie, Angiologie und Intensivmedizin, Hindenburgdamm 30, 12203, Berlin, Germany.
German Center for Cardiovascular Research (DZHK), Partner Site Berlin, Berlin, Germany.
Berlin Institute of Health Center for Regenerative Therapies (BCRT), 13353, Berlin, Germany.

Sara Hadzibegovic (S)

Charité - Universitätsmedizin Berlin, Corporate Member of Freie Universität Berlin and Humboldt-Universität zu Berlin, Charitéplatz 1, 10117, Berlin, Germany.
Deutsches Herzzentrum der Charité, Klinik für Kardiologie, Angiologie und Intensivmedizin, Hindenburgdamm 30, 12203, Berlin, Germany.
German Center for Cardiovascular Research (DZHK), Partner Site Berlin, Berlin, Germany.
Berlin Institute of Health Center for Regenerative Therapies (BCRT), 13353, Berlin, Germany.

Annalen Bleckmann (A)

Department of Haematology and Medical Oncology, University of Göttingen Medical Center (UMG), 37075, Göttingen, Germany.
West German Cancer Center, University Hospital Münster, 48149, Münster, Germany.
Department of Medicine A for Hematology, Oncology and Pneumology, University Hospital Münster, 48149, Muenster, Germany.

Ulrich Keller (U)

Department of Hematology, Oncology and Cancer Immunology, Charité - Universitätsmedizin Berlin, Campus Benjamin Franklin, 12203, Berlin, Germany.
German Cancer Consortium (DKTK) & German Cancer Research Center (DKFZ), 69120, Heidelberg, Germany.
Max-Delbrück-Center for Molecular Medicine, 13125, Berlin, Germany.

Ulf Landmesser (U)

Charité - Universitätsmedizin Berlin, Corporate Member of Freie Universität Berlin and Humboldt-Universität zu Berlin, Charitéplatz 1, 10117, Berlin, Germany.
Deutsches Herzzentrum der Charité, Klinik für Kardiologie, Angiologie und Intensivmedizin, Hindenburgdamm 30, 12203, Berlin, Germany.
German Center for Cardiovascular Research (DZHK), Partner Site Berlin, Berlin, Germany.
Berlin Institute of Health (BIH), 13353, Berlin, Germany.

Alexander O König (AO)

Department of Gastroenterology, University of Göttingen Medical Center (UMG), 37075, Göttingen, Germany.

Gerd Hasenfuss (G)

Department of Cardiology and Pneumology, University of Göttingen Medical Center (UMG), Georg-August-University Göttingen, Robert-Koch-Str. 40, 37075, Göttingen, Germany.
German Center for Cardiovascular Research (DZHK), Partner Site Göttingen, Göttingen, Germany.

Andreas Schuster (A)

Department of Cardiology and Pneumology, University of Göttingen Medical Center (UMG), Georg-August-University Göttingen, Robert-Koch-Str. 40, 37075, Göttingen, Germany.
German Center for Cardiovascular Research (DZHK), Partner Site Göttingen, Göttingen, Germany.
ORCID: 0000-0003-1508-1125

Markus S Anker (MS)

Charité - Universitätsmedizin Berlin, Corporate Member of Freie Universität Berlin and Humboldt-Universität zu Berlin, Charitéplatz 1, 10117, Berlin, Germany.
Deutsches Herzzentrum der Charité, Klinik für Kardiologie, Angiologie und Intensivmedizin, Hindenburgdamm 30, 12203, Berlin, Germany.
German Center for Cardiovascular Research (DZHK), Partner Site Berlin, Berlin, Germany.
Berlin Institute of Health Center for Regenerative Therapies (BCRT), 13353, Berlin, Germany.

Stephan von Haehling (S)

Department of Cardiology and Pneumology, University of Göttingen Medical Center (UMG), Georg-August-University Göttingen, Robert-Koch-Str. 40, 37075, Göttingen, Germany. stephan.von.haehling@web.de.
German Center for Cardiovascular Research (DZHK), Partner Site Göttingen, Göttingen, Germany. stephan.von.haehling@web.de.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female

Evaluation of Low-Value Services Across Major Medicare Advantage Insurers and Traditional Medicare.

Ciara Duggan, Adam L Beckman, Ishani Ganguli et al.
1.00
Humans United States Aged Cross-Sectional Studies Medicare Part C

Effectiveness of Virtual Yoga for Chronic Low Back Pain: A Randomized Clinical Trial.

Hallie Tankha, Devyn Gaskins, Amanda Shallcross et al.
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH

questionsmedicales.fr › Eucaryotes › Animaux › Chordés › Vertébrés › Mammifères › Eutheria › Primates › Haplorhini › Catarrhini › Hominidae › Humains › Predictors of lower exercise capacity in...
questionsmedicales.fr › Phénomènes physiologiques de l'appareil locomoteur et du système nerveux › Phénomènes physiologiques du système locomoteur › Tolérance à l'effort › Predictors of lower exercise capacity in...
questionsmedicales.fr › Phénomènes physiologiques de l'appareil locomoteur et du système nerveux › Phénomènes physiologiques du système locomoteur › Force musculaire › Force de la main › Predictors of lower exercise capacity in...
questionsmedicales.fr › Acides aminés, peptides et protéines › Protéines › Protéines du cytosquelette › Protéines des microfilaments › Troponine › Troponine T › Predictors of lower exercise capacity in...
questionsmedicales.fr › Tumeurs › Predictors of lower exercise capacity in...
questionsmedicales.fr › Environnement et santé publique › Santé publique › Mesures épidémiologiques › Biométrie › Anthropométrie › Indice de masse corporelle › Predictors of lower exercise capacity in...